Savient Stock Hits New 52-Week Low (SVNT)

NEW YORK (TheStreet) -- Savient Pharmaceuticals (Nasdaq:SVNT) hit a new 52-week low Tuesday as it is currently trading at $2.02, below its previous 52-week low of $2.04 with 391,443 shares traded as of 10:45 a.m. ET. Average volume has been 1.6 million shares over the past 30 days.

Savient has a market cap of $168.7 million and is part of the health care sector and drugs industry. Shares are down 5.4% year to date as of the close of trading on Monday.

Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company in the United States. It engages in developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients refractory to conventional therapy.

• Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Savient as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow, generally disappointing historical performance in the stock itself and generally weak debt management. You can view the full Savient Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

 

For more information on Savient Pharmaceuticals click any of the following:

• Savient Pharmaceuticals Stock Price

• Savient Pharmaceuticals Analyst Ratings

• Savient Pharmaceuticals Key Stats & Profile

• Savient Pharmaceuticals Earnings

• Savient Pharmaceuticals Ratio Comparison

• Savient Pharmaceuticals Growth Rates

• Savient Pharmaceuticals Balance Sheet

• Savient Pharmaceuticals Cash Flow

• Savient Pharmaceuticals Income Statement